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De-escalation and escalation therapeutic strategies are commonly employed by clinicians on the basis of
susceptibility results and patient response. Since no in vitro or in vivo data are currently available to support
one strategy over the other for daptomycin, we attempted to evaluate the effects of dose escalation and
de-escalation on daptomycin activity against methicillin-resistant Staphylococcus aureus (MRSA) isolates using
an in vitro pharmacokinetic/pharmacodynamic (PK/PD) model with simulated endocardial vegetations. Three
clinical MRSA isolates, including one heterogeneous vancomycin-intermediate S. aureus (hVISA) isolate and
one vancomycin-intermediate S. aureus (VISA) isolate, were exposed to daptomycin at 10 or 6 mg/kg of body
weight/day for 8 days using a starting inoculum of 109 CFU/g of vegetations, with dose escalation and
de-escalation initiated on the fourth day. Daptomycin MIC values ranged from 0.5 to 1 g/ml. In the PK/PD
model, high-dose daptomycin (10 mg/kg/day) and de-escalation simulation (10 to 6 mg/kg/day) appeared to be
the most efficient regimens against the three tested isolates, exhibiting the fastest bactericidal activity (4 to 8 h)
compared to that of the standard regimen of 6 mg/kg/day and the escalation therapy of 6 to 10 mg/kg/day. The
differences in the numbers of CFU/g observed between dose escalation and de-escalation were significant for
the hVISA strain, with the de-escalation simulation exhibiting a better killing effect than the escalation
simulation (P < 0.024). Although our results need to be carefully considered, the use of high-dose daptomycin
up front demonstrated the most efficient activity against the tested isolates. Different therapeutic scenarios
including isolates with higher MICs and prolonged drug exposures are warranted to better understand the
outcomes of escalation and de-escalation strategies.
Methicillin-resistant Staphylococcus aureus (MRSA) infec-
tions have been increasingly reported in both the community
and hospital settings and currently represent a serious health
care threat (3, 30). Over the last decades, antibiotic overuse
and misuse have largely contributed to the emergence of mul-
tidrug-resistant (MDR) pathogens by exerting a selective pres-
sure on microorganisms present in the environment (24, 38).
Independent of infection control measures, carefully consid-
ered antibiotic usage has proved to be highly beneficial in
reducing the emergence of resistance (23, 33). Thus, imple-
mentation of antimicrobial stewardship programs internation-
ally has been proposed to promote judicious use of antimicro-
bials and preserve the current anti-infective arsenal (2, 37).
However, strategies developed to tackle the antibiotic resis-
tance vary from country to country and within the different
health care settings in the same country, highlighting the need
for collective measures (5).
Daptomycin is one of the few options currently available to
treat serious infections caused by MDR S. aureus, including
isolates with reduced susceptibility to vancomycin (31, 41). The
Food and Drug Administration approved the doses of 4 and 6
mg/kg of body weight/day over a 30-min intravenous infusion
for complicated skin and soft tissue infections (cSSSIs) and
bloodstream infections, respectively (Cubicin package insert,
Cubist Pharmaceuticals). However, despite the judicious ther-
apeutic use of this agent in the past 7 years, isolates of MRSA
with reduced susceptibility to daptomycin have emerged. In a
recent and extensive review of the literature, Falagas et al.
reported seven daptomycin-nonsusceptible isolates over 60
clinical cases of endocarditis and bacteremia (13), including
four MRSA strains recovered from patients who previously
received vancomycin and three vancomycin-resistant entero-
cocci (13). Although the rate of resistance to daptomycin is a
significantly lower than that to most antimicrobials, it appears
to be essential to optimize the use of this drug and limit the risk
of emergence of nonsusceptible organisms (32). Clinicians of-
ten start daptomycin therapy using the approved dosage of 6
mg/kg/day and then increase the dose if the patient’s clinical
and/or microbiological response is not adequate (19, 20, 29).
Depending on the site of infection and the ability of the anti-
microbial to reach the site in adequate concentrations, the
strategy of dose escalation may be comparable to the gradient
exposure method commonly used in laboratory-based science
to encourage the development of resistance in vitro (6). On the
other hand, daptomycin has been proved to be a potent con-
centration-dependent bactericidal agent, and use of high-dose
daptomycin initially may limit the development of resistance
through its more rapid bactericidal activity (7, 34). Postmar-
keting observational studies evaluating the efficacy and safety
of high-dose daptomycin in difficult-to-treat S. aureus infec-
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tions have reported promising results (29). As an alternative to
clinical investigations, we report in this study on the effect of
dose escalation and de-escalation on daptomycin’s in vitro ac-
tivity against three clinical isolates of MRSA, including one
vancomycin-intermediate S. aureus (VISA) strain and one het-
erogeneous vancomycin-intermediate S. aureus (hVISA)
strain.
(This study was presented in part at the 49th Interscience
Conference on Antimicrobial Agents and Chemotherapy, San
Francisco, CA, 2009, poster A1-1272.)
MATERIALS AND METHODS
Bacterial strains. A total of three clinical MRSA were selected from the
Anti-Infective Research Laboratory MRSA collection. Isolates included one
vancomycin- and daptomycin-susceptible MRSA isolate (B010-01, recovered
from a patient at the Ohio State University Medical Center in 2009), one
hVISA isolate (R3099, recovered from the bloodstream of a patient of the
Detroit Medical Center in 2005), and one VISA isolate (NRS-118, from the Net-
work on Antimicrobial Resistance in Staphylococcus aureus collection). The
hVISA characteristic of R3099 was confirmed by use of a modified population
analysis profile and Mu3 as a reference strain, as previously described by Woot-
ton et al. (data not shown) (42) The VISA phenotype of NRS-118 was confirmed
by macro-Etest, as described elsewhere (25).
Antimicrobials. Daptomycin analytical powder (Cubist Pharmaceuticals, Inc.,
Lexington, MA) was provided by its manufacturer, whereas vancomycin was
commercially purchased from Sigma-Aldrich (St. Louis, MO). Drug stock solu-
tions were freshly prepared every day according to the CLSI guidelines (10) or
the manufacturer’s recommendations.
Media. Due to daptomycin’s dependence on calcium for antimicrobial activity,
Mueller-Hinton (MH) broth (Difco, Detroit, MI) supplemented with 50 or 75
g/ml calcium and 12.5 g/ml magnesium (50 and 75 SMHB, respectively) was
used for all susceptibility testing and in vitro pharmacokinetic/pharmacodynamic
(PK/PD) models evaluating daptomycin, respectively (22). Tryptic soy agar
(TSA; Difco, Detroit, MI) and Mueller-Hinton agar (Difco, Detroit, MI) plates
were used for colony counting and detection of emergence of resistance, respec-
tively.
Susceptibility testing. MICs of daptomycin and vancomycin were determined
in duplicate by broth microdilution at 5.5  105 CFU/ml, as recommended by
the CLSI guidelines (10).
Pharmacokinetic/pharmacodynamic models. The previously described in vitro
PK/PD model with simulated endocardial vegetations (SEVs) was used to eval-
uate the effects of de-escalation and escalation regimens on daptomycin’s killing
activity against three clinical isolates of S. aureus (27). Briefly, the central cham-
ber of the apparatus containing 32 SEVs was prefilled with 75 SMHB and
maintained at 37°C in a water bath. SEVs were prepared as previously described
by mixing the organism suspension, human cryoprecipitate from volunteer do-
nors (American Red Cross, Detroit, MI), platelets, and bovine thrombin. This
mixture resulted in simulated vegetations containing a starting bacterial burden
of 109 CFU/g with approximately 3 to 3.5 g/dl of albumin and 6.8 to 7.4 g/dl of
total protein (1). Daptomycin was administered as daily boluses over a 192-h
period via an injection port. A magnetic stir bar was placed in the central
compartment to ensure mixing of the drug throughout the procedure. Fresh
medium was continuously supplied and removed from the compartment along
with the drug via a peristaltic pump (Masterflex; Cole-Parmer Instrument Com-
pany, Chicago, IL) set to simulate the half-life of daptomycin (targeted at 8 h) (4)
A total of four regimens were evaluated in duplicate for each isolate to ensure
reproducibility and included daptomycin simulations of 10 mg/kg/day (peak
concentration, 129.7 g/ml) (4) for 4 days followed by 6 mg/kg/day (peak con-
centration, 95.7 g/ml) (4) for 4 days, daptomycin simulations of 6 mg/kg/day for
4 days followed by 10 mg/kg/day for 4 days, daptomycin simulations of 10
mg/kg/day for 8 days, and daptomycin simulations of 6 mg/kg/day for 8 days.
Total drug concentrations were used, since all experiments were performed in
the presence of a concentration of albumin simulated to match that in humans.
A growth control was performed for each isolate to ensure viability of the
organisms through the experiment.
Pharmacodynamic analysis. Two simulated endocardial vegetations (total of
four) were removed at 0, 4, 8, 24, 32, 48, 56, and 72 h for days 0 to 3 and 0, 4, 8,
24, 32, 48, 56, 72, and 96 h for days 4 to 8. The SEVs were homogenized, diluted
in cold normal saline, and plated onto TSA plates to allow colony counting.
When serial dilution did not prevent antibiotic carryover, samples were vacuum
filtered through a 0.45-m-pore-size filter before they were plated, therefore
reducing the antibiotic concentration below the MIC of the drug. We determined
these methods to have a lower limit of reliable detection of 1 log10 CFU/g. Plates
were incubated at 35°C for 24 h, at which time colony counts were performed.
The total reduction in log10 CFU/g over 192 h was determined by plotting
time-kill curves on the basis of the number of remaining organisms over the time
period. Bactericidal activity (99.9% kill) and bacteriostatic activity were defined
as 3-log10 CFU/g and 3-log10 CFU/g reductions in the colony count from the
initial inoculum, respectively. Inactivity was defined as no observed reductions
from the initial inoculum. The time required to achieve a 99.9% bacterial load
reduction was determined by linear regression (if r2 was 0.95) or visual
inspection.
Pharmacokinetic analysis. Samples for pharmacokinetic analysis were ob-
tained through the injection port at 0.5, 1, 2, 4, 8, 24, 32, 48, 56, and 72 for days
0 to 3 and 4 to 8 for verification of target antibiotic concentrations. All samples
were stored at 70°C until they were ready for analysis. Concentrations of
daptomycin were determined by microbioassay utilizing Micrococcus luteus
ATCC 9341, as previously described (35). This assay demonstrated a lower limit
of detection of 5 g/ml and interday and intraday coefficients of variation less
than or equal to 10% for 50-, 100-, and 200-g/ml standards. The half-life, area
under the curve (AUC), and peak (maximum) concentration (Cmax) were deter-
mined by the trapezoidal method utilizing PK Analyst software (version 1.10;
MicroMath Scientific Software, Salt Lake City, UT).
Resistance. Development of resistance was evaluated throughout the simula-
tion at multiple time points every 24 h. Briefly, at each time point 100-l samples
were plated on MH agar plates supplemented with calcium (final concentration,
50 mg/liter) and containing 3 MIC of daptomycin. Plates were examined for
growth after 24 and 48 h of incubation at 35°C. Any growth observed was tested
for changes in susceptibility by both Etest and the microdilution method accord-
ing to the CLSI recommendations (10).
Statistical analysis. Changes in the numbers of CFU/g between regimens at
24, 48, and 72 h for days 1 to 3 and 96, 120, 144, 168, and 192 h for days 4 to 8
were compared by two-way analysis of variance with Tukey’s post hoc test using
SPSS statistical software (release 18.0; SPSS, Inc., Chicago, IL). A P value of
0.05 was considered significant.
RESULTS
Daptomycin MIC values were 0.5, 1, and 1 g/ml for VISA
NRS-118, B010-01, and hVISA R3099, respectively. Except for
VISA NRS-118 (MIC  4 g/ml), the vancomycin MIC of all
isolates was 2 g/ml (Table 1). No change in daptomycin MIC
TABLE 1. In vitro activity of daptomycin against 3 isolates
of MRSA
Isolate no.
(DAP MIC g/ml) Regimen
a
Change in log10 CFU/g from
starting inoculum at:
96 h 192 h
B010-01 (1) D6 5.31 	 0.25 3.62 	 0.61
D6-10 4.68 	 0.47 8.20 	 0.00
D10 8.57 	 0.22 8.70 	 0.00
D10-6 8.18 	 0.00 8.18 	 0.00
R3099 (1) D6 5.10 	 0.35 4.96 	 0.04
D6-10 5.35 	 0.21 4.88 	 0.42
D10 6.75 	 0.12 5.87 	 0.42
D10-6 6.87 	 0.09 5.59 	 0.13
VISA NRS-118 (0.5) D6 4.89 	 0.39 5.18 	 0.56
D6-10 3.94 	 0.61 5.02 	 0.27
D10 7.16 	 0.09 7.55
D10-6 6.85 	 0.09 6.44 	 0.14
a D6, daptomycin at 6 mg/kg/day for 8 days; D6-10, daptomycin at 6 mg/
kg/day for 4 days followed by 10 mg/kg/day for 4 days; D10, daptomycin at 10
mg/kg/day for 8 days; D10-6, daptomycin at 10 mg/kg/day for 4 days followed by
6 mg/kg/day for 4 days.
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was observed throughout the 8-day period of daptomycin ex-
posure for any of the 3 isolates tested.
Pharmacokinetic analysis demonstrated the accuracy of the
models performed, with Cmax and half-life values being within
10% of the targeted values. The total peak concentrations
observed were 127.37 	 2.1 and 96.4 	 2.3 g/ml for dapto-
mycin regimens of 10 and 6 mg/kg/day, respectively, and the
daptomycin half-life was approximately 7.35 	 0.33 h. In terms
of pharmacodynamic activity, daptomycin demonstrated a con-
centration-dependent effect and sustained bactericidal activity,
although some variability between strains was observed over
the 8 days of drug exposure (Fig. 1). Depending on the regi-
men used to start the simulations, daptomycin achieved 99.9%
of the killing between 4 and 32 h, with the highest dose of 10
mg/kg/day exhibiting the most rapid cidal effect (between 4 and
8 h). Against B010-01, the use of daptomycin at 10 mg/kg/day
up front or applied 4 days after the dose of 6 mg/kg/day held
the bacterial population down significantly, reaching the limit
of detection at 56 h (Fig. 1A). In contrast, the use of a regimen
of 6 mg/kg/day for 8 days significantly reduced the killing ac-
tivity of daptomycin, with a 4-log10-CFU/g bacterial regrowth
observed at 152 h. No change in MIC was observed at this
point, but the population analysis profile revealed a shift to-
ward the highest MIC within the population following a stan-
dard dose of 6 mg/kg/day for 8 days (Fig. 2, dashed lines). In
contrast, escalation to a dose of 10 mg/kg/day at 96 h after 4
days with a dose of 6 mg/kg/day resulted in a significant killing
effect, with the bacterial burden achieving the limit of detec-
tion at 152 h and no colonies being detected at 192 h (Fig. 1A).
Against hVISA isolate R3099, daptomycin regimens of 10 mg/
kg/day and 10 to 6 mg/kg/day resulted in more effective killing
effects than the regimens of 6 mg/kg/day and 6 to 10 mg/kg/day
(Fig. 1B). Except at 128 and 192 h, the differences between
escalation and de-escalation were statistically significant (P 
0.02), with the de-escalation regimen resulting in greater ac-
tivity than the escalation regimen. Analysis of the initial pop-
ulation MICs revealed a heterogeneous profile for susceptibil-
ity to daptomycin and the presence of subpopulations with
higher MICs, which may explain the reduced activity of 10
mg/kg/day for the hVISA isolate than the MRSA strain (Fig. 2,
open squares). Finally, against VISA isolate NRS-118, the
killing effect observed with the dose de-escalation regimen
appeared to be slightly greater than the activity resulting from
the escalation simulation (Fig. 1C). Except at 100 and 120 h,
the difference between the two regimens was not statistically
significant (P 
 0.05), but bactericidal activity was achieved
much more rapidly with the de-escalation regimen or dapto-
mycin at 10 mg/kg/day up front. Similar to the findings for
hVISA strain R3099, no increase in MIC was observed at the
end of the experiment, and the heterogeneous profile of the
initial population might explain the reduced activity of dapto-
mycin and the small differences between the regimens evalu-
ated (Fig. 2, open diamonds).
DISCUSSION
It is well-recognized that the PK and PD parameters of a
drug play a key role in the success or failure of a therapy as well
as in the emergence or the selection of resistant subpopula-
tions (16, 40). In this study, we aimed to investigate how spe-
FIG. 1. In vitro activity of daptomycin. (A) B010-01; (B) hVISA
R3099; (C) VISA NRS-118. Filled circles, growth control; open circles,
daptomycin at 10 mg/kg/day; open triangles, daptomycin at 10 to 6
mg/kg/day; filled inverted triangles, daptomycin at 6 mg/kg/day; filled
squares, daptomycin at 6 to 10 mg/kg/day. The vertical dashed line
represents the time for de-escalation or escalation therapy, if it was
performed.
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cific PK changes as a result of escalation or de-escalation of the
dose regimens would affect the killing activity of daptomycin
against isolates of MRSA in the context of a simulated high
inoculum burden, such as those found in infective endocarditis.
Consistent with previously published data, we observed dapto-
mycin concentration-dependent bactericidal activity against all
MRSA isolates, including strains with reduced susceptibility to
vancomycin (26, 34). Also consistent with previous results from
our group (26), in comparison with the results for the stan-
dard dose (6 mg/kg/day), high-dose daptomycin (10 mg/kg/
day) achieved a more rapid and the greatest killing effect
against all isolates, reaching the limit of detection (i.e., less
than 10 CFU/g of vegetation) at 56 h for one isolate. Despite
some limitations, including evaluation of a small number of
isolates and a short length of therapy (8 days in vitro versus at
least 4 weeks in vivo) (15), our data tend to support the use of
high-dose daptomycin up front with a potential for use of a
de-escalation dosage.
Bactericidal antimicrobials are usually preferred to bacterio-
static antibiotics for the treatment of infective endocarditis.
The reasons behind this rationale include the limited host
defenses at the site of infection as well as the need for rapid
bacterial eradication to shorten the therapy and reduce the risk
of resistance, relapse, or complications (12). The importance
of rapid bacterial clearance has recently been explored by
Chang et al. in a prospective observational study that included
505 patients with S. aureus bacteremia (9). Patients were mon-
itored for 6 months and up to 3 years in order to identify any
relapse or reinfection episodes secondary to vancomycin or
nafcillin therapy. In all patients with methicillin-susceptible
S. aureus bacteremia, nafcillin therapy appeared to be superior
to vancomycin therapy with respect to persistent bacteremia
and/or relapse prevention. Infective endocarditis was reported
to be one of the risk factors for relapse of S. aureus bacteremia,
and a multivariate analysis of treatment demonstrated that
vancomycin was an independent predictor of relapse (P  0.05
or 6.5; 95% confidence interval, 1.0 to 52.8). Chang et al.
concluded that a more rapid clearance of bacteremia is asso-
ciated with a lower likelihood of complications (9). These
results were recently confirmed by Khatib et al. (18) and high-
light the importance of rapid bacterial eradication in the treat-
ment of complicated bacteremia, including infective endocar-
ditis. The temporal relationship between antibiotic therapy and
the occurrence of complications secondary to infective endo-
carditis has not yet been clearly investigated. However, recent
data report that patients (about 40%) with left-sided endocar-
ditis may experienced cerebrovascular complications in the
first 10 days following the initiation of appropriate antibiotic
therapy and before sterilization of the endocardial vegetations
(9, 14, 15). Such complications can still occur during the first
week, despite adequate treatment. However, the fact that the
risk of complication is rapidly decreased after initiation of the
administration of antibiotics supports a faster sterilization of
the vegetation and clearance of the bacteremia to reduce the
risk of embolization and relapse (12).
Reports of daptomycin-nonsusceptible strains of MRSA in
the past few years, especially in patients with bacterial endo-
carditis, emphasize the need to optimize therapy to achieve
clinical success (17, 21, 39, 43). The mechanism responsible for
the reduced susceptibility of these isolates to daptomycin is not
completely understood. Increased expression of specific loci in-
volved in membrane thickness, composition, and charges, such as
dltABCD (43) and mprF (21), has been suggested. Previous
exposure to vancomycin leading to reduced bactericidal in vitro
activity of daptomycin (11, 32) has also been reported, with the
subsequent emergence of daptomycin-nonsusceptible isolates
secondary to daptomycin exposure (39). We recently reported
on the superiority of a dose of 10 mg/kg/day over one of 6
mg/kg/day using an in vitro model of SEVs, with the develop-
ment of reduced susceptibility to daptomycin occurring using a
dose of 6 mg/kg/day, whereas a dose of 10 mg/kg/day prevented
the emergence of such isolates (36). Similar results were re-
ported with a clinical daptomycin-nonsusceptible strain se-
lected in vivo with a dose of 6 mg/kg/day, and in vitro time-kill
assays performed with 8 g/ml (equal to a free concentration
of a 6-mg/kg/day dose regimen) showed that bactericidal ac-
tivity against this isolate was retained (39). Finally, in a rabbit
model of endocarditis, Chambers et al. reported on the poten-
tial for higher efficacy from a 10-mg/kg/day dose, irrespective
of the daptomycin susceptibility profile of the strain (8). Taken
together, these data suggest that high-dose daptomycin may
prevent the selection or development of isolates with reduced
susceptibility to daptomycin and therefore subsequent clinical
failure. Our data also suggest that the use of de-escalation
from high-dose daptomycin to 6 mg/kg/day and continuous
high-dose daptomycin at 10 mg/kg/day demonstrated similar
results. This may indicate that sustained use of 10 mg/kg/day
throughout the treatment may not be necessary and may not
offer an advantage from the standpoint of improved safety.
Although clinicians may be more comfortable with the prac-
tice of escalating dosages when patients do not respond ini-
tially, the use of off-label high-dose daptomycin (i.e., 10 mg/
FIG. 2. Daptomycin population analysis profiles. Open triangles,
B010-01 at 0 h; open circles, B010-01 at 192 h; open squares, R3099 at
0 h, open diamonds, NRS-118 at 0 h.
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kg/day) up front may present more challenges. Therefore,
clinicians will need to weigh the risks and benefits of this
dosing procedure. Observational data from high-dose dapto-
mycin use would suggest that it may be safe; however, there are
no large-scale clinical trials at this point to confirm this initial
information, so caution is warranted.
In conclusion, because we observed a more rapid reduction
of the bacterial burden in the SEVs with high-dose daptomycin
(10 mg/kg/day) applied continuously or de-escalated to 6 mg/
kg/day, this strategy may lead to a faster cure of bacteremia in
vivo and to prevention of the emergence of reduced suscepti-
bility to daptomycin. The findings in the increasing inventory of
reports recently published also suggest the potential for the
efficacy and safety of high-dose daptomycin and support the
conclusions of the present study (4, 28). Use of a de-escalation
strategy could eventually be considered a reasonable alterna-
tive, but in vivo investigations are warranted to determine the
appropriate length of high-dose daptomycin that would ensure
the sterilization of the vegetations, preventing further infec-
tious embolus complications and the development of nonsus-
ceptible strains.
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